Cetera Investment Advisers raised its stake in shares of GSK plc (NYSE:GSK – Free Report) by 1.2% during the 2nd quarter, Holdings Channel.com reports. The institutional investor owned 76,298 shares of the pharmaceutical company’s stock after acquiring an additional 883 shares during the quarter. Cetera Investment Advisers’ holdings in GSK were worth $2,719,000 as of its most recent SEC filing.
Several other institutional investors also recently bought and sold shares of GSK. Dimensional Fund Advisors LP boosted its position in shares of GSK by 11.5% during the 2nd quarter. Dimensional Fund Advisors LP now owns 1,700,885 shares of the pharmaceutical company’s stock valued at $60,605,000 after acquiring an additional 175,731 shares in the last quarter. Veritable L.P. acquired a new position in GSK during the 2nd quarter valued at about $203,000. Highland Capital Management LLC acquired a new position in GSK in the second quarter valued at about $794,000. Fisher Asset Management LLC grew its stake in GSK by 4.3% in the second quarter. Fisher Asset Management LLC now owns 13,824,592 shares of the pharmaceutical company’s stock valued at $492,994,000 after acquiring an additional 571,088 shares during the period. Finally, Synovus Financial Corp grew its stake in GSK by 3.5% in the second quarter. Synovus Financial Corp now owns 126,241 shares of the pharmaceutical company’s stock valued at $4,499,000 after acquiring an additional 4,272 shares during the period. 13.53% of the stock is currently owned by institutional investors.
GSK Stock Performance
NYSE:GSK opened at $35.11 on Tuesday. The company has a quick ratio of 0.70, a current ratio of 0.95 and a debt-to-equity ratio of 1.27. GSK plc has a twelve month low of $33.17 and a twelve month high of $39.74. The firm has a market capitalization of $71.89 billion, a PE ratio of 9.44, a price-to-earnings-growth ratio of 1.65 and a beta of 0.66. The stock’s 50-day simple moving average is $36.05 and its 200 day simple moving average is $35.44.
GSK Cuts Dividend
Analyst Ratings Changes
Separately, StockNews.com raised shares of GSK from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, November 1st. Three investment analysts have rated the stock with a sell rating, three have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $1,553.75.
GSK plc, together with its subsidiaries, engages in the research, development and manufacture of vaccines and specialty medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare.
- Five stocks we like better than GSK
- Want to Profit on the Downtrend? Downtrends, Explained.
- Membership clubs gain leverage for the consumer rebound
- Manufacturing Stocks Investing
- Advanced Auto Parts may be worth more in pieces than the whole
- What Are Meme Stocks and Are They Viable Investments?
- The Trade Desk train returns to the station
Receive News & Ratings for GSK Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GSK and related companies with MarketBeat.com's FREE daily email newsletter.